5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas

Jiheng Zhang, Nan Wang, Jiasheng Wu, Xin Gao, Hongtao Zhao, Zhihui Liu, Xiuwei Yan, Jiawei Dong, Fang Wang, Yixu Ba, Shuai Ma, Jiaqi Jin, Jianyang Du, Hang Ji, Shaoshan HuFrontiers in Immunology 2022 · DOI

TL;DR

This study introduces a novel "m5C-related lncRNA signature" (m5CrLS) that effectively predicts prognosis in lower-grade gliomas (LGG). This signature not only reveals distinct molecular and immune characteristics of LGG subtypes but also shows promise in guiding treatment decisions for temozolomide and immune checkpoint blockade therapies.

What Problem Does This Paper Address?

Lower-grade gliomas (LGGs) present significant challenges in clinical management due to their invasive nature, frequent relapses, and potential for malignant transformation. While some biomarkers exist, there's a persistent need for better diagnostic, prognostic, and therapeutic tools. This paper addresses the gap in understanding the complex interplay between RNA modifications (specifically 5-methylcytosine, or m5C), long non-coding RNAs (lncRNAs), and the tumor microenvironment in LGG, aiming to uncover new insights for improved patient outcomes.

Methods

The researchers employed a multi-faceted approach:

  • Data Mining and Analysis: They analyzed large-scale datasets from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) to identify m5C regulators and lncRNAs.
  • Statistical Modeling: Univariate Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression were used to identify prognostic lncRNAs and construct the m5CrLS.
  • Bioinformatic Tools: Various bioinformatics tools and R packages were utilized for differential expression analysis, protein-protein interaction network construction, functional enrichment analysis (GO, KEGG), and immune cell infiltration estimation (TIMER2.0, ssGSEA, TIP).
  • Predictive Modeling: Receiver Operating Characteristic (ROC) curves and Kaplan-Meier (K-M) analyses were used to assess the predictive power of the m5CrLS for prognosis and treatment response.

Datasets

  • TCGA (The Cancer Genome Atlas): Used for mRNA expression profiles, transcriptomic data, clinicopathological data, and somatic mutation data.
  • CGGA (Chinese Glioma Genome Atlas): Used for mRNA expression profiles and clinicopathological data.
  • GTEx (Genotype-Tissue Expression) database: Used for normal brain tissue expression data.

Key Insights and Ideas

  • m5C-lncRNA Axis in LGG: The study establishes a significant link between m5C modification regulators and lncRNAs in LGG, suggesting a coordinated regulatory network influencing tumor progression.
  • Prognostic Power of m5CrLS: The developed m5C-related lncRNA signature (m5CrLS) demonstrates robust predictive capability for patient survival, outperforming traditional clinical factors.
  • Immune Microenvironment Stratification: The m5CrLS effectively stratifies LGG patients into distinct immune profiles, with high-score patients exhibiting increased immune infiltration but paradoxically decreased anti-tumor immunity, indicating a complex immunosuppressive landscape.
  • Therapeutic Sensitivity Prediction: The m5CrLS shows promise in predicting response to both temozolomide (TMZ) chemotherapy and immune checkpoint blockade (ICB) therapy, offering a potential tool for personalized treatment selection.

Key Results

  • Four Prognostic lncRNAs Identified: LINC00265, CIRBP-AS1, GDNF-AS1, and ZBTB20-AS4 were identified as key m5C-related lncRNAs with prognostic significance.
  • m5CrLS Performance: The m5CrLS demonstrated high predictive accuracy, with 1-year AUC values of 0.854 (TCGA) and 0.740 (CGGA), and was an independent risk factor for LGG.
  • Immune Cell Infiltration: High m5CrLS scores were associated with increased infiltration of various immune cells, including myeloid dendritic cells, but also with signs of immunosuppression.
  • Treatment Response: Low m5CrLS scores predicted improved survival in patients receiving TMZ and a better response to ICB therapy.

Limitations and Future Work

The authors acknowledge several limitations:

  • In Vitro/In Vivo Validation: Further experimental validation of the identified lncRNAs, m5C modification sites, and specific mechanisms in cellular and tissue models is needed.
  • Multicenter Clinical Trials: The m5CrLS requires validation in larger, prospective, and multicenter clinical trials to establish its clinical utility.
  • Mechanism of ICPs: While the study links m5CrLS to immune checkpoint expression, the specific mechanisms by which m5C modifications influence ICPs remain to be elucidated.

Future work should focus on these areas to fully translate these findings into clinical practice.

Summary updated

Abstract

5-Methylcytosine (m5C) methylation is an important RNA modification pattern that can participate in oncogenesis and progression of cancers by affecting RNA stability, expression of oncogenes, and the activity of cancer signaling pathways. Alterations in the expression pattern of long non-coding RNAs (lncRNAs) are potentially correlated with abnormalities in the m5C regulation features of cancers. Our aim was to reveal the mechanisms by which lncRNAs regulated the m5C process, to explore the impact of aberrant regulation of m5C on the biological properties of lower-grade gliomas (LGG), and to optimize current therapeutic. By searching 1017 LGG samples from the Cancer Genome Atlas and Chinese Glioma Genome Atlas, we first clarified the potential impact of m5C regulators on LGG prognosis in this study and used univariate Cox analysis and least absolute shrinkage and selection operator regression to explore clinically meaningful lncRNAs. Consequently, we identified four lncRNAs, including LINC00265, CIRBP-AS1, GDNF-AS1, and ZBTB20-AS4, and established a novel m5C-related lncRNAs signature (m5CrLS) that was effective in predicting prognosis. Notably, mutation rate, WHO class II, IDH mutation, 1p/19q co-deletion and MGMT promoter methylation were increased in the low m5CrLS score group. Patients with increased m5CrLS scores mostly showed activation of tumor malignancy-related pathways, increased immune infiltrating cells, and decreased anti-tumor immune function. Besides, the relatively high expression of immune checkpoints also revealed the immunosuppressed state of patients with high m5CrLS scores. In particular, m5CrLS stratification was sensitive to assess the efficacy of LGG to temozolomide and the responsiveness of immune checkpoint blockade. In conclusion, our results revealed the molecular basis of LGG, provided valuable clues for our understanding of m5C-related lncRNAs, and filled a gap between epigenetics and tumor microenvironment.
BibTeX
@inproceedings{zhang2022methylcytosine,
  author = {Jiheng Zhang and Nan Wang and Jiasheng Wu and Xin Gao and Hongtao Zhao and Zhihui Liu and Xiuwei Yan and Jiawei Dong and Fang Wang and Yixu Ba and Shuai Ma and Jiaqi Jin and Jianyang Du and Hang Ji and Shaoshan Hu},
  title = {{5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.844778},
}
Figure